# Mineralys Therapeutics, Inc.: financial statements, quarterly

MLYS · Nasdaq · CIK 1933414 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mlys.md) · [Financials](/companies/mlys/financials.md) · [Filings](/companies/mlys/filings.md) · [Insiders](/companies/mlys/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mlys/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [22.5](/filings/0001933414-24-000057.md) | [23.7 d](/filings/0001933414-25-000009.md) | [30.8](/filings/0001933414-25-000058.md) | [39.3](/filings/0001933414-25-000090.md) | [54.0](/filings/0001933414-25-000142.md) | [44.6 d](/filings/0001933414-26-000056.md) | [37.9](/filings/0001933414-26-000084.md) | [38.3](/filings/0001933414-26-000114.md) | [31.5](/filings/0001933414-25-000142.md) | [24.4 d](/filings/0001933414-26-000056.md) | [24.4](/filings/0001933414-26-000084.md) | [221](/filings/0001933414-26-000114.md) |
| Operating income | $m | [(26.3)](/filings/0001933414-24-000057.md) | [(27.7) d](/filings/0001933414-25-000009.md) | [(35.4)](/filings/0001933414-25-000058.md) | [(45.2)](/filings/0001933414-25-000090.md) | [(60.1)](/filings/0001933414-25-000142.md) | [(51.8) d](/filings/0001933414-26-000056.md) | [(44.4)](/filings/0001933414-26-000084.md) | [(46.7)](/filings/0001933414-26-000114.md) | [(41.1)](/filings/0001933414-25-000142.md) | [(38.3) d](/filings/0001933414-26-000056.md) | [(45.3)](/filings/0001933414-26-000084.md) | [(246)](/filings/0001933414-26-000114.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001933414-26-000056.md) | not reported | not reported |
| Net income | $m | [(22.8)](/filings/0001933414-24-000057.md) | [(24.4) d](/filings/0001933414-25-000009.md) | [(31.5)](/filings/0001933414-25-000142.md) | [(41.0)](/filings/0001933414-25-000142.md) | [(56.3)](/filings/0001933414-25-000142.md) | [(48.9) d](/filings/0001933414-26-000056.md) | [(42.2)](/filings/0001933414-26-000114.md) | [(43.3)](/filings/0001933414-26-000114.md) | [(36.9)](/filings/0001933414-25-000142.md) | [(32.2) d](/filings/0001933414-26-000056.md) | [(39.3)](/filings/0001933414-26-000114.md) | [(241)](/filings/0001933414-26-000114.md) |
| Diluted EPS | $ per share | [(0.57)](/filings/0001933414-24-000057.md) | not reported | [(0.70)](/filings/0001933414-25-000058.md) | [(0.83)](/filings/0001933414-25-000090.md) | [(1.13)](/filings/0001933414-25-000142.md) | not reported | [(0.79)](/filings/0001933414-26-000084.md) | [(0.66)](/filings/0001933414-26-000114.md) | [(0.52)](/filings/0001933414-25-000142.md) | not reported | [(0.47)](/filings/0001933414-26-000084.md) | [(2.85)](/filings/0001933414-26-000114.md) |
| Basic EPS | $ per share | [(0.57)](/filings/0001933414-24-000057.md) | not reported | [(0.70)](/filings/0001933414-25-000058.md) | [(0.83)](/filings/0001933414-25-000090.md) | [(1.13)](/filings/0001933414-25-000142.md) | not reported | [(0.79)](/filings/0001933414-26-000084.md) | [(0.66)](/filings/0001933414-26-000114.md) | [(0.52)](/filings/0001933414-25-000142.md) | not reported | [(0.47)](/filings/0001933414-26-000084.md) | [(2.85)](/filings/0001933414-26-000114.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [86.3](/filings/0001933414-23-000087.md) | [49.3](/filings/0001933414-25-000009.md) | [90.4](/filings/0001933414-24-000016.md) | [67.9](/filings/0001933414-24-000039.md) | [97.3](/filings/0001933414-24-000057.md) | [114](/filings/0001933414-26-000056.md) | [165](/filings/0001933414-25-000058.md) | [102](/filings/0001933414-25-000090.md) | [218](/filings/0001933414-25-000142.md) | [173](/filings/0001933414-26-000114.md) | [113](/filings/0001933414-26-000084.md) | [138](/filings/0001933414-26-000114.md) |
| Current assets | $m | [265](/filings/0001933414-23-000087.md) | [249](/filings/0001933414-25-000009.md) | [347](/filings/0001933414-24-000016.md) | [318](/filings/0001933414-24-000039.md) | [268](/filings/0001933414-24-000057.md) | [205](/filings/0001933414-26-000056.md) | [355](/filings/0001933414-25-000058.md) | [335](/filings/0001933414-25-000090.md) | [600](/filings/0001933414-25-000142.md) | [661](/filings/0001933414-26-000114.md) | [652](/filings/0001933414-26-000084.md) | [666](/filings/0001933414-26-000114.md) |
| Total assets | $m | [278](/filings/0001933414-23-000087.md) | [252](/filings/0001933414-25-000009.md) | [347](/filings/0001933414-24-000016.md) | [318](/filings/0001933414-24-000039.md) | [268](/filings/0001933414-24-000057.md) | [206](/filings/0001933414-26-000056.md) | [355](/filings/0001933414-25-000058.md) | [336](/filings/0001933414-25-000090.md) | [600](/filings/0001933414-25-000142.md) | [662](/filings/0001933414-26-000114.md) | [653](/filings/0001933414-26-000084.md) | [668](/filings/0001933414-26-000114.md) |
| Current liabilities | $m | [13.5](/filings/0001933414-23-000087.md) | [10.5](/filings/0001933414-25-000009.md) | [19.2](/filings/0001933414-24-000016.md) | [28.4](/filings/0001933414-24-000039.md) | [31.3](/filings/0001933414-24-000057.md) | [14.6](/filings/0001933414-26-000056.md) | [13.4](/filings/0001933414-25-000058.md) | [22.2](/filings/0001933414-25-000090.md) | [23.5](/filings/0001933414-25-000142.md) | [15.1](/filings/0001933414-26-000114.md) | [14.7](/filings/0001933414-26-000084.md) | [19.3](/filings/0001933414-26-000114.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [15.1](/filings/0001933414-26-000114.md) | not reported | [117](/filings/0001933414-26-000114.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.1](/filings/0001933414-26-000114.md) |
| Shareholders' equity | $m | [264](/filings/0001933414-24-000057.md) | [241](/filings/0001933414-26-000056.md) | [328](/filings/0001933414-25-000142.md) | [290](/filings/0001933414-25-000142.md) | [237](/filings/0001933414-25-000142.md) | [191](/filings/0001933414-26-000114.md) | [342](/filings/0001933414-26-000114.md) | [314](/filings/0001933414-26-000114.md) | [576](/filings/0001933414-25-000142.md) | [647](/filings/0001933414-26-000114.md) | [638](/filings/0001933414-26-000114.md) | [551](/filings/0001933414-26-000114.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(19.0) d](/filings/0001933414-24-000057.md) | [(29.0) d](/filings/0001933414-25-000009.md) | [(19.1)](/filings/0001933414-25-000058.md) | [(30.1) d](/filings/0001933414-25-000090.md) | [(50.2) d](/filings/0001933414-25-000142.md) | [(66.8) d](/filings/0001933414-26-000056.md) | [(45.5)](/filings/0001933414-26-000084.md) | [(30.2) d](/filings/0001933414-26-000114.md) | [(28.9) d](/filings/0001933414-25-000142.md) | [(37.9) d](/filings/0001933414-26-000056.md) | [(39.5)](/filings/0001933414-26-000084.md) | [(32.6) d](/filings/0001933414-26-000114.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001933414-24-000057.md) | [0.0 d](/filings/0001933414-25-000009.md) | [0.1](/filings/0001933414-25-000058.md) | [0.0 d](/filings/0001933414-25-000090.md) | [0.0 d](/filings/0001933414-25-000142.md) | [0.0 d](/filings/0001933414-26-000056.md) | [0.0](/filings/0001933414-25-000058.md) | [0.0 d](/filings/0001933414-25-000090.md) | [0.0 d](/filings/0001933414-25-000142.md) | [0.0 d](/filings/0001933414-26-000056.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets

## Shares

| Line item | Unit | period not labelled (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [5.2](/filings/0001933414-23-000087.md) | [24.8](/filings/0001933414-24-000016.md) | [39.8](/filings/0001933414-24-000039.md) | [39.9](/filings/0001933414-24-000057.md) | [44.9](/filings/0001933414-25-000058.md) | [49.4](/filings/0001933414-25-000090.md) | [49.8](/filings/0001933414-25-000142.md) | [53.2](/filings/0001933414-26-000084.md) | [65.5](/filings/0001933414-26-000114.md) | [70.6](/filings/0001933414-25-000142.md) | [82.8](/filings/0001933414-26-000084.md) | [84.7](/filings/0001933414-26-000114.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 88,406,885 at 2026-08-03, from the cover of the [10-Q filed 2026-08-11](/filings/0001933414-26-000114.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.